BR112014004182A2 - métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição - Google Patents

métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição

Info

Publication number
BR112014004182A2
BR112014004182A2 BR112014004182A BR112014004182A BR112014004182A2 BR 112014004182 A2 BR112014004182 A2 BR 112014004182A2 BR 112014004182 A BR112014004182 A BR 112014004182A BR 112014004182 A BR112014004182 A BR 112014004182A BR 112014004182 A2 BR112014004182 A2 BR 112014004182A2
Authority
BR
Brazil
Prior art keywords
hepatitis
treating hepatitis
treating
virus
preventing
Prior art date
Application number
BR112014004182A
Other languages
English (en)
Portuguese (pt)
Inventor
Voitenleitner Christian
Walker Jill
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112014004182A2 publication Critical patent/BR112014004182A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014004182A 2011-08-24 2012-08-24 métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição BR112014004182A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US201261617813P 2012-03-30 2012-03-30
PCT/US2012/052216 WO2013028953A1 (en) 2011-08-24 2012-08-24 Combination treatments for hepatitis c

Publications (1)

Publication Number Publication Date
BR112014004182A2 true BR112014004182A2 (pt) 2017-03-14

Family

ID=47746891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004182A BR112014004182A2 (pt) 2011-08-24 2012-08-24 métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição

Country Status (18)

Country Link
US (1) US20140234253A1 (https=)
EP (1) EP2747569A4 (https=)
JP (2) JP2014527061A (https=)
KR (1) KR20140065427A (https=)
CN (1) CN103917095A (https=)
AU (1) AU2012298750A1 (https=)
BR (1) BR112014004182A2 (https=)
CA (1) CA2845321A1 (https=)
CL (1) CL2014000428A1 (https=)
CO (1) CO6890100A2 (https=)
CR (1) CR20140086A (https=)
EA (1) EA201490254A1 (https=)
HK (1) HK1198869A1 (https=)
IL (1) IL230844A0 (https=)
MX (1) MX2014002171A (https=)
PH (1) PH12014500386A1 (https=)
SG (1) SG2014010490A (https=)
WO (1) WO2013028953A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201290089A1 (ru) 2009-09-04 2012-09-28 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Химические соединения
BR112014003556A2 (pt) * 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP6333372B2 (ja) * 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015096674A1 (zh) * 2013-12-23 2015-07-02 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
US9512108B2 (en) * 2013-12-31 2016-12-06 Nanjing Sanhome Pharmaceutical Co., Ltd. 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof
CN106279122A (zh) * 2014-01-21 2017-01-04 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业（浙江）有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CN102271699A (zh) * 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
PT3309157T (pt) * 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
EA201290089A1 (ru) * 2009-09-04 2012-09-28 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Химические соединения
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20120118008A (ko) * 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
US20120070411A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs

Also Published As

Publication number Publication date
AU2012298750A1 (en) 2014-03-13
KR20140065427A (ko) 2014-05-29
IL230844A0 (en) 2014-03-31
CL2014000428A1 (es) 2014-08-01
JP2014527061A (ja) 2014-10-09
SG2014010490A (en) 2014-04-28
MX2014002171A (es) 2014-04-25
EA201490254A1 (ru) 2014-07-30
PH12014500386A1 (en) 2019-10-07
EP2747569A1 (en) 2014-07-02
WO2013028953A1 (en) 2013-02-28
CO6890100A2 (es) 2014-03-10
CA2845321A1 (en) 2013-02-28
HK1198869A1 (en) 2015-06-19
JP2017165746A (ja) 2017-09-21
CN103917095A (zh) 2014-07-09
US20140234253A1 (en) 2014-08-21
EP2747569A4 (en) 2015-07-08
CR20140086A (es) 2014-05-02

Similar Documents

Publication Publication Date Title
BR112014004182A2 (pt) métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
BR112014009528A2 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112014025726A2 (pt) mecanismo, sistema e método para tratamento endodôntico
BR112014013246A8 (pt) composição catalisadora, e, método para tratar nox
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112013018679A2 (pt) agente para o tratamento da alopecia
BR112014007963A2 (pt) aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatite
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral
BR112014031896A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um distúrbio
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
BR112013029514A2 (pt) composição imunogênica, vacina, e, método de tratar ou impedir uma doença
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014025339A8 (pt) método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.
BR112014015598A2 (pt) método para tratar uma porção de um poço, e, fluido de tratamento
BR112014015549A2 (pt) composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
BRPI0924398A2 (pt) perexilina, metodo de tratamento de hfnef e programa de tratamento para tratar hfnef

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.